Molecular profile
Molecular profile
- Molecule class
- Peptide analogue
- Origin
- Synthetic analogue
- Primary target system
- GHRH-Rezeptor und GH/IGF-1-Achse
- Development stage
- Clinical development
Modifiziertes GHRH-Analogon; Varianten mit und ohne Drug-Affinity-Complex werden häufig vermischt.
Mechanism and signalling
Mechanism and signalling
The peptides stimulate the GHRH receptor. The DAC design additionally aims to prolong albumin binding and exposure.
Scientific classification
Scientific classification
This profile maps CJC-1295 to the research areas endocrine, metabolism. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.
Peptide hormones and analogues related to hypothalamic, pituitary and peripheral endocrine systems.
Pathways related to glucose homeostasis, appetite, energy expenditure and body composition.
Evidence base
Early human data
Small early human studies examined pharmacokinetics and endocrine markers. Robust controlled evidence for common non-medical claims is lacking.
Regulatory status
Not generally authorised
This research substance has no general medicinal authorisation in Germany or the EU. Labels such as “research peptide” do not replace regulatory approval.
Safety and use notice
No dosing or administration recommendation
The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.
Sources and registries